Search
Digoxigenin
go.drugbank.com/drugs/DB03671ExperimentalDigoxigenin is a cardenolide which is the aglycon of digoxin. Can be obtained by hydrolysis of digoxin or from Digitalis orientalis L. and Digitalis lanata Ehrh.
Categories: P-glycoprotein substratesCarfilzomib
go.drugbank.com/drugs/DB08889ApprovedInvestigationalCarfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treat...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesMirabegron
go.drugbank.com/drugs/DB08893ApprovedInvestigationalMirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, ...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesTofacitinib
go.drugbank.com/drugs/DB08895ApprovedInvestigationalTofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid a...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesPonatinib
go.drugbank.com/drugs/DB08901ApprovedInvestigationalPonatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesCanagliflozin
go.drugbank.com/drugs/DB08907ApprovedInvestigationalCanagliflozin, also known as Invokana, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approv...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsPerospirone
go.drugbank.com/drugs/DB08922InvestigationalPerospirone is an atypical or second-generation antipsychotic of the azapirone family that antagonizes serotonin 5HT2A receptors and dopamine D2 receptors. It also displays affinity towards 5HT1A receptors as a partial agonist. Dainippon...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesMacitentan
go.drugbank.com/drugs/DB08932ApprovedInvestigationalMacitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH). It was first approved by the FDA in 2013. Macitentan differs from its predecessor bosentan in part due to its lower risk ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesAzosemide
go.drugbank.com/drugs/DB08961InvestigationalAzosemide is a loop diuretic used to treat hypertension, edema, and ascites.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates